LUF8100 is a dual-target antagonist of CCR2/CCR5 with pKi values for CCR2 and CCR5 of 5.23 and 4.97 respectively.
Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMSO) | $98.00 | In Stock | 1 | |
| 5mg | $89.00 | In Stock | 1 | |
| 10mg | $130.00 | In Stock | 1 | |
| 25mg | $235.00 | In Stock | 1 | |
| 50mg | $373.00 | In Stock | 1 |
LUF8100 is a dual-target antagonist of CCR2/CCR5 with pKi values for CCR2 and CCR5 of 5.23 and 4.97 respectively. LUF8100 can be used for research on immune homeostasis and cancer[1].
References:
[1]. Essa K, et al. Combining AlphaFold with Focused Virtual Library Design in the Development of Novel CCR2 and CCR5 Antagonists. J Chem Inf Model. 2025 Nov 24;65(22):12398-12409.